IL17A and Autoimmunity: As monoclonal antibody therapies targeting cytokines or B-cell pathways (e.g. anti-TNF agents, anti-IL-17, anti-BAFF therapies) have transformed the management of autoimmune conditions, future studies should assess whether these biologics might benefit subgroups of COPD patients with strong autoimmune phenotypes.